Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?
Med
; 5(3): 184-186, 2024 Mar 08.
Article
em En
| MEDLINE
| ID: mdl-38460498
ABSTRACT
Favorable results were achieved in a phase 3 clinical trial (IMerge) with the telomerase inhibitor imetelstat in transfusion-dependent patients with lower-risk myelodysplastic syndromes (MDSs) who relapsed or were refractory to erythropoiesis-stimulating agents.1 Imetelstat is likely to become a useful addition to our limited therapeutic options for patients with MDS.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
Limite:
Humans
Idioma:
En
Revista:
Med
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Alemanha